ClinVar Miner

Submissions for variant NM_001370259.2(MEN1):c.654+1G>T

dbSNP: rs794728622
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000182411 SCV000234754 pathogenic not provided 2016-09-07 criteria provided, single submitter clinical testing The c.654+1 G>T splice site variant in the MEN1 gene has been previously reported in association with multiple endocrine neoplasia type 1 (MEN1) (for examples, see Teh et al., 1998a; Teh et al., 1998b; Cardinal et al., 2005). This variant destroys the canonical splice donor site in intron 3, and is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. Based on currently available evidence, we consider c.654+1G>T to be pathogenic.
Mendelics RCV000709159 SCV000838458 pathogenic Multiple endocrine neoplasia, type 1 2018-07-02 criteria provided, single submitter clinical testing
Invitae RCV000709159 SCV000963141 pathogenic Multiple endocrine neoplasia, type 1 2018-07-18 criteria provided, single submitter clinical testing Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MEN1 are known to be pathogenic (PMID: 12112656, 17853334). For these reasons, this variant has been classified as Pathogenic. This variant has been observed in several individuals and families affected with multiple endocrine neoplasia type 1 (PMID: 9709921, 15635078, 9064485, 9671073). This variant is also known as IVS3+1G>T in the literature. ClinVar contains an entry for this variant (Variation ID: 200978). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 3 of the MEN1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product.
Ambry Genetics RCV002362934 SCV002658973 pathogenic Hereditary cancer-predisposing syndrome 2017-05-26 criteria provided, single submitter clinical testing The c.654+1G>T intronic pathogenic mutation results from a G to T substitution one nucleotide after coding exon 2 of the MEN1 gene. This alteration has been identified multiple unrelated families with MEN1 (Teh BT et al. J. Clin. Endocrinol. Metab., 1998 Aug;83:2621-6; Ambry Internal Data). Another variant at this donor site, c.654+1G>A, has also been seen in families with MEN1 and RNA studies showed that the c.654+1G>A variant leads to an alternatively spliced transcript with a 35 amino acid deletion (Canaff L et al. J. Biol. Chem., 2012 Mar;287:8584-97). In addition, functional studies conducted by this same group showed that lymphoblastoid cells expressing the resulting mutant protein showed increased cell proliferation and had a defective TGF-β response. This alteration was previously identified in an Australian MEN1 family (Teh BT et al. J. Clin. Endocrinol. Metab. 1998 Aug;83:2621-6). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.